SynapDx

NEW YORK (GenomeWeb News) – SynapDx today announced a collaboration with the Broad Institute to develop next-generation sequencing analysis methods to improve autism diagnostics.

NEW YORK (GenomeWeb News) – The Massachusetts Life Sciences Center has released the list of firms that will receive a total of $25 million in tax incentives tied to job creation this year, and that list includes several omics and molecular diagnostics firms.

Paired Ends: Kevin Hrusovsky

Premium

SynapDx has appointed Kevin Hrusovsky to the firm's board of directors. He most recently served as president of life sciences and technology at PerkinElmer.

SynapDx said this week that Mark DePristo has joined the Lexington, Mass.-based company as vice pres

Illumina has appointed Richard Klausner to senior vice president and Chief Medical Officer, where he will lead Illumina's strategies for advancing genomics into clinical medicine and public health.

Illumina has appointed Richard Klausner to senior vice president and Chief Medical Officer, where he will lead Illumina's strategies for advancing genomics into clinical medicine and public health.

Companies that sell or are developing microarray-based tests for early stage autism diagnosis will soon face off against a competitor with a next-generation sequencing-based offering.

SynapDx this week appointed Andrew Conrad to the company's board of directors.

NEW YORK (GenomeWeb News) – Autism diagnostics firm SynapDx today said that it raised $15.4 million.

NEW YORK (GenomeWeb News) – SynapDx this week said that it has received a "significant investment" from The Kraft Group that will support ongoing clinical development of its molecular diagnostic test for autism spectrum disorder.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.